Aimmune Therapeutics (AIMT +3.6%) announces positive data from a follow-on study to its Phase 3 PALISADE trial of peanut allergy product Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp].
At year 2, patients dosed daily showed ongoing
immunomodulation and higher rates of desensitization that increased over
time compared to non-daily-dosed patients while experiencing lower
rates of adverse events. 80% of these patients who underwent a food
challenge demonstrated desensitization to 2,000 mg of peanut protein
(~14 kernels), higher than the non-daily group.
The FDA approved Palforzia in January.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.